US Patent 11168058 Manufacture of a crystalline pharmaceutical product
Patent 11168058 was granted and assigned to Orion Corporation on November, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+507 characters)
Article
Patent abstract
The present disclosure relates to crystalline particles of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) having specific surface area (SSA) in the range from about 8 to about 16 m2/g, preferably from about 10 to about 15 m2/g, and to the method for the preparation of such particles. Compound (I) is a potent androgen receptor (AR) modulator which is useful as a medicament for example in the treatment of prostate cancer.
Edits on 10 Oct, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Anna Staffans0
Merja Reunanen0
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 7 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
111680580
Date of Patent
November 9, 2021
0Patent Application Number
201802270
Date Filed
February 27, 2018
0Official Website
Patent Primary Examiner
Edits on 7 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 11 Nov, 2021
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11168058 Manufacture of a crystalline pharmaceutical product
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11168058
Date of patent
November 9, 2021
Patent application number
20180227
Date Filed
February 27, 2018
Patent primary examiner
Find more entities like US Patent 11168058 Manufacture of a crystalline pharmaceutical product
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
